An engineered Mycoplasma pneumoniae to fight Staphylococcus aureus

Bacterial infections are commonly treated with antimicrobials, but the rise of multi‐drug resistance and the presence of biofilms can compromise treatment efficacy. Recently, new approaches using live bacteria or engineered microorganisms have gained attention in the fight against several diseases....

Full description

Saved in:
Bibliographic Details
Published in:Molecular systems biology 2021-10, Vol.17 (10), p.e10574-n/a
Main Authors: Matteau, Dominick, Rodrigue, Sébastien
Format: Article
Language:English
Subjects:
Animals
Anti-Bacterial Agents - pharmacology
Antibiotics
Antimicrobial agents
Bacterial diseases
Biofilms
Catheters
Chemical compounds
Drug resistance
EMBO23
EMBO41
Experiments
Genes
Genetic engineering
Genetic modification
Genetically engineered microorganisms
Laboratories
Mice
Microbial Sensitivity Tests
Microorganisms
Mycoplasma pneumoniae
Mycoplasma pneumoniae - genetics
News & Views
Organisms
Pathogens
Pharmacology
Staphylococcus aureus
Staphylococcus aureus - genetics
Staphylococcus infections
Synthetic biology
Views
Virulence
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Bacterial infections are commonly treated with antimicrobials, but the rise of multi‐drug resistance and the presence of biofilms can compromise treatment efficacy. Recently, new approaches using live bacteria or engineered microorganisms have gained attention in the fight against several diseases. In their recent work, Lluch‐Senar and colleagues (Garrido et al , 2021) genetically modified the lung pathogen Mycoplasma pneumoniae to attenuate its virulence and secrete antibiofilm and bactericidal enzymes. Their strategy successfully altered a Staphylococcus aureus biofilm on catheters implanted in mice, providing an additional demonstration of the potential of genetically engineered microorganisms as therapeutic agents. Graphical Abstract Multi‐drug resistance and the presence of biofilms can compromise antimicrobial treatment efficacy. In their recent work, Lluch‐Senar and colleagues (Garrido et al , 2021) engineered the lung pathogen M. pneumoniae to secrete antibiofilm and bactericidal enzymes.
ISSN:1744-4292
1744-4292
DOI:10.15252/msb.202110574